Is XGN or GMRS more profitable?

GMR Solutions has a net margin of 0.00% compared to Exagen's net margin of -26.61%. GMR Solutions' return on equity of 0.00% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% GMR Solutions N/A N/A N/A

Does the media refer more to XGN or GMRS?

In the previous week, GMR Solutions had 3 more articles in the media than Exagen. MarketBeat recorded 5 mentions for GMR Solutions and 2 mentions for Exagen. Exagen's average media sentiment score of 1.79 beat GMR Solutions' score of 0.69 indicating that Exagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive GMR Solutions 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is FLGT or XGN more profitable?

Fulgent Genetics has a net margin of -26.05% compared to Exagen's net margin of -26.61%. Fulgent Genetics' return on equity of -4.93% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Fulgent Genetics -26.05% -4.93% -4.50% Exagen -26.61% -104.46% -28.93%

Does the media favor FLGT or XGN?

In the previous week, Fulgent Genetics had 4 more articles in the media than Exagen. MarketBeat recorded 6 mentions for Fulgent Genetics and 2 mentions for Exagen. Exagen's average media sentiment score of 1.79 beat Fulgent Genetics' score of 1.01 indicating that Exagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exagen 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher earnings and valuation, XGN or SBC?

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 2.76 -$19.95M -$0.81 N/A SBC Medical Group $175.17M 2.42 $50.99M $0.47 8.77

Is XGN or SBC more profitable?

SBC Medical Group has a net margin of 27.99% compared to Exagen's net margin of -26.61%. SBC Medical Group's return on equity of 18.47% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% SBC Medical Group 27.99% 18.47% 13.10%

Does the media prefer XGN or SBC?

In the previous week, SBC Medical Group had 1 more articles in the media than Exagen. MarketBeat recorded 3 mentions for SBC Medical Group and 2 mentions for Exagen. Exagen's average media sentiment score of 1.79 beat SBC Medical Group's score of 0.62 indicating that Exagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SBC Medical Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, VMD or XGN?

Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viemed Healthcare $301.61M 1.15 $14.93M $0.36 25.22 Exagen $66.57M 2.76 -$19.95M -$0.81 N/A

Is VMD or XGN more profitable?

Viemed Healthcare has a net margin of 4.81% compared to Exagen's net margin of -26.61%. Viemed Healthcare's return on equity of 10.16% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Viemed Healthcare 4.81% 10.16% 7.22% Exagen -26.61% -104.46% -28.93%

Does the media refer more to VMD or XGN?

In the previous week, Viemed Healthcare and Viemed Healthcare both had 2 articles in the media. Exagen's average media sentiment score of 1.79 beat Viemed Healthcare's score of 1.59 indicating that Exagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viemed Healthcare 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Exagen 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Exagen (XGN) Competitors

$7.58 +0.04 (+0.53%)

As of 09/4/2026 04:00 PM Eastern

Compare

XGN vs. GMRS, FLGT, SRTA, SBC, and VMD

Should you buy Exagen stock or one of its competitors? Exagen's main competitors and comparable companies include GMR Solutions (GMRS), Fulgent Genetics (FLGT), Strata Critical Medical (SRTA), SBC Medical Group (SBC), and Viemed Healthcare (VMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Exagen compare to GMR Solutions?

Exagen (NASDAQ:XGN) and GMR Solutions (NYSE:GMRS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Exagen has higher earnings, but lower revenue than GMR Solutions. Exagen is trading at a lower price-to-earnings ratio than GMR Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	2.76	-$19.95M	-$0.81	N/A
GMR Solutions	$5.88B	0.12	-$84.27M	-$1.56	N/A

In the previous week, GMR Solutions had 3 more articles in the media than Exagen. MarketBeat recorded 5 mentions for GMR Solutions and 2 mentions for Exagen. Exagen's average media sentiment score of 1.79 beat GMR Solutions' score of 0.69 indicating that Exagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
GMR Solutions	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.3% of Exagen shares are held by institutional investors. 10.4% of Exagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Exagen currently has a consensus price target of $9.63, suggesting a potential upside of 26.98%. GMR Solutions has a consensus price target of $18.67, suggesting a potential upside of 38.48%. Given GMR Solutions' higher possible upside, analysts clearly believe GMR Solutions is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
GMR Solutions	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

GMR Solutions has a net margin of 0.00% compared to Exagen's net margin of -26.61%. GMR Solutions' return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
GMR Solutions	N/A	N/A	N/A

Summary

Exagen beats GMR Solutions on 8 of the 15 factors compared between the two stocks.

How does Exagen compare to Fulgent Genetics?

Fulgent Genetics (NASDAQ:FLGT) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Fulgent Genetics has a net margin of -26.05% compared to Exagen's net margin of -26.61%. Fulgent Genetics' return on equity of -4.93% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
Exagen	-26.61%	-104.46%	-28.93%

48.1% of Fulgent Genetics shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 36.2% of Fulgent Genetics shares are held by insiders. Comparatively, 10.4% of Exagen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Fulgent Genetics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Exagen has a beta of 2.1, indicating that its stock price is 110% more volatile than the broader market.

In the previous week, Fulgent Genetics had 4 more articles in the media than Exagen. MarketBeat recorded 6 mentions for Fulgent Genetics and 2 mentions for Exagen. Exagen's average media sentiment score of 1.79 beat Fulgent Genetics' score of 1.01 indicating that Exagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exagen	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Fulgent Genetics currently has a consensus price target of $27.50, suggesting a potential upside of 39.38%. Exagen has a consensus price target of $9.63, suggesting a potential upside of 26.98%. Given Fulgent Genetics' higher probable upside, equities analysts plainly believe Fulgent Genetics is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Exagen has lower revenue, but higher earnings than Fulgent Genetics. Exagen is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.68	-$60.51M	-$2.82	N/A
Exagen	$66.57M	2.76	-$19.95M	-$0.81	N/A

Summary

Exagen beats Fulgent Genetics on 9 of the 17 factors compared between the two stocks.

How does Exagen compare to Strata Critical Medical?

Strata Critical Medical (NASDAQ:SRTA) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Strata Critical Medical has a beta of 2.26, suggesting that its share price is 126% more volatile than the broader market. Comparatively, Exagen has a beta of 2.1, suggesting that its share price is 110% more volatile than the broader market.

47.4% of Strata Critical Medical shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 15.5% of Strata Critical Medical shares are held by company insiders. Comparatively, 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Strata Critical Medical has a net margin of 15.71% compared to Exagen's net margin of -26.61%. Strata Critical Medical's return on equity of -2.97% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Strata Critical Medical	15.71%	-2.97%	-2.54%
Exagen	-26.61%	-104.46%	-28.93%

Strata Critical Medical has higher revenue and earnings than Exagen. Strata Critical Medical is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Strata Critical Medical	$197.14M	2.39	$41.35M	-$0.04	N/A
Exagen	$66.57M	2.76	-$19.95M	-$0.81	N/A

Strata Critical Medical currently has a consensus target price of $8.00, suggesting a potential upside of 50.38%. Exagen has a consensus target price of $9.63, suggesting a potential upside of 26.98%. Given Strata Critical Medical's higher probable upside, equities analysts plainly believe Strata Critical Medical is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Strata Critical Medical	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Exagen had 2 more articles in the media than Strata Critical Medical. MarketBeat recorded 2 mentions for Exagen and 0 mentions for Strata Critical Medical. Exagen's average media sentiment score of 1.79 beat Strata Critical Medical's score of 0.00 indicating that Exagen is being referred to more favorably in the news media.

Company	Overall Sentiment
Strata Critical Medical	Neutral
Exagen	Very Positive

Summary

Strata Critical Medical beats Exagen on 9 of the 16 factors compared between the two stocks.

How does Exagen compare to SBC Medical Group?

Exagen (NASDAQ:XGN) and SBC Medical Group (NASDAQ:SBC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Exagen has a beta of 2.1, meaning that its stock price is 110% more volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

75.3% of Exagen shares are owned by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are owned by institutional investors. 10.4% of Exagen shares are owned by insiders. Comparatively, 81.7% of SBC Medical Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

SBC Medical Group has a net margin of 27.99% compared to Exagen's net margin of -26.61%. SBC Medical Group's return on equity of 18.47% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
SBC Medical Group	27.99%	18.47%	13.10%

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	2.76	-$19.95M	-$0.81	N/A
SBC Medical Group	$175.17M	2.42	$50.99M	$0.47	8.77

In the previous week, SBC Medical Group had 1 more articles in the media than Exagen. MarketBeat recorded 3 mentions for SBC Medical Group and 2 mentions for Exagen. Exagen's average media sentiment score of 1.79 beat SBC Medical Group's score of 0.62 indicating that Exagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
SBC Medical Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exagen presently has a consensus price target of $9.63, indicating a potential upside of 26.98%. SBC Medical Group has a consensus price target of $8.50, indicating a potential upside of 106.31%. Given SBC Medical Group's higher possible upside, analysts plainly believe SBC Medical Group is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
SBC Medical Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

SBC Medical Group beats Exagen on 10 of the 17 factors compared between the two stocks.

How does Exagen compare to Viemed Healthcare?

Viemed Healthcare (NASDAQ:VMD) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Viemed Healthcare has a net margin of 4.81% compared to Exagen's net margin of -26.61%. Viemed Healthcare's return on equity of 10.16% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viemed Healthcare	4.81%	10.16%	7.22%
Exagen	-26.61%	-104.46%	-28.93%

In the previous week, Viemed Healthcare and Viemed Healthcare both had 2 articles in the media. Exagen's average media sentiment score of 1.79 beat Viemed Healthcare's score of 1.59 indicating that Exagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viemed Healthcare	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Exagen	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

74.2% of Viemed Healthcare shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 20.6% of Viemed Healthcare shares are held by company insiders. Comparatively, 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Viemed Healthcare presently has a consensus target price of $14.00, indicating a potential upside of 54.19%. Exagen has a consensus target price of $9.63, indicating a potential upside of 26.98%. Given Viemed Healthcare's higher possible upside, analysts plainly believe Viemed Healthcare is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viemed Healthcare	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Viemed Healthcare has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Exagen has a beta of 2.1, suggesting that its stock price is 110% more volatile than the broader market.

Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viemed Healthcare	$301.61M	1.15	$14.93M	$0.36	25.22
Exagen	$66.57M	2.76	-$19.95M	-$0.81	N/A

Summary

Viemed Healthcare beats Exagen on 9 of the 16 factors compared between the two stocks.

Get Exagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XGN vs. The Competition

Export

Metric	Exagen	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$182.66M	$10.10B	$7.26B	$12.90B
Dividend Yield	N/A	2.59%	2.53%	8.90%
P/E Ratio	-9.36	34.60	273.83	25.45
Price / Sales	2.76	4.85	607.44	79.03
Price / Cash	N/A	121.75	77.39	52.28
Price / Book	15.16	3.99	12.85	6.17
Net Income	-$19.95M	$313.25M	$3.49B	$350.08M
7 Day Performance	2.57%	1.06%	1.04%	-0.14%
1 Month Performance	13.98%	0.33%	5.52%	1.02%
1 Year Performance	-21.61%	15.31%	24.39%	14.51%

Exagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XGN Exagen	3.8643 of 5 stars	$7.58 +0.5%	$9.63 +27.0%	-22.9%	$182.66M	$66.57M	N/A	220	Positive News
GMRS GMR Solutions	4.9174 of 5 stars	$13.35 -0.4%	$18.67 +39.8%	N/A	$721.17M	N/A	N/A	N/A	Positive News
FLGT Fulgent Genetics	3.2373 of 5 stars	$19.56 -0.5%	$27.50 +40.6%	-10.2%	$538.10M	$322.67M	N/A	1,315	News Coverage Positive News
SRTA Strata Critical Medical	1.992 of 5 stars	$5.36 -0.3%	$8.00 +49.4%	N/A	$473.76M	$197.14M	N/A	130
SBC SBC Medical Group	4.1326 of 5 stars	$4.07 -5.0%	$8.50 +109.1%	+1.2%	$419.22M	$173.61M	8.67	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XGN) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exagen (XGN) Competitors

XGN vs. GMRS, FLGT, SRTA, SBC, and VMD

How does Exagen compare to GMR Solutions?

Summary

How does Exagen compare to Fulgent Genetics?

Summary

How does Exagen compare to Strata Critical Medical?

Summary

How does Exagen compare to SBC Medical Group?

Summary

How does Exagen compare to Viemed Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exagen (XGN) Competitors

XGN vs. GMRS, FLGT, SRTA, SBC, and VMD

How does Exagen compare to GMR Solutions?

Which has higher earnings & valuation, XGN or GMRS?

Does the media refer more to XGN or GMRS?

Do insiders & institutionals believe in XGN or GMRS?

Do analysts rate XGN or GMRS?

Is XGN or GMRS more profitable?

Summary

How does Exagen compare to Fulgent Genetics?

Is FLGT or XGN more profitable?

Do insiders and institutionals hold more shares of FLGT or XGN?

Which has more risk & volatility, FLGT or XGN?

Does the media favor FLGT or XGN?

Do analysts rate FLGT or XGN?

Which has higher valuation & earnings, FLGT or XGN?

Summary

How does Exagen compare to Strata Critical Medical?

Which has more volatility and risk, SRTA or XGN?

Do institutionals & insiders hold more shares of SRTA or XGN?

Is SRTA or XGN more profitable?

Which has higher earnings & valuation, SRTA or XGN?

Do analysts prefer SRTA or XGN?

Does the media favor SRTA or XGN?

Summary

How does Exagen compare to SBC Medical Group?

Which has more volatility and risk, XGN or SBC?

Do institutionals and insiders have more ownership in XGN or SBC?

Is XGN or SBC more profitable?

Which has higher earnings and valuation, XGN or SBC?

Does the media prefer XGN or SBC?

Do analysts recommend XGN or SBC?

Summary

How does Exagen compare to Viemed Healthcare?

Is VMD or XGN more profitable?

Does the media refer more to VMD or XGN?

Do institutionals & insiders have more ownership in VMD or XGN?

Do analysts recommend VMD or XGN?

Which has more volatility & risk, VMD or XGN?

Which has higher valuation and earnings, VMD or XGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools